BMS-955176 + dolutegravir

**BMS-955176 + dolutegravir** is an investigational combination therapy for HIV-1 infection consisting of two antiretrovirals. **BMS-955176** is a second-generation HIV-1 maturation inhibitor which targets the final stage of Gag processing by inhibiting HIV-1 protease cleavage at the CA/SP1 junction, thereby blocking virus maturation and the production of infectious viral particles. **Dolutegravir** is an integrase strand transfer inhibitor (INSTI) that prevents the integration of viral DNA into the host genome. The combination is being evaluated particularly in populations with multi-class resistance or prior treatment experience, aiming to combine high barrier-to-resistance (from dolutegravir) with a novel mechanism of action (from BMS-955176). Clinical studies up to phase 2 have examined the safety, efficacy, and pharmacokinetics of this combination[2][3][4].